Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1-Reference-Cited by-同舟云学术

Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1

Published:2018-05-02 Issue:10 Volume:61 Page:4635-4640
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Humphrey John M.¹^ORCID,Movsesian Matthew²,am Ende Christopher W.¹^ORCID,Becker Stacey L.¹,Chappie Thomas A.³,Jenkinson Stephen⁴,Liras Jennifer L.³,Liras Spiros³,Orozco Christine¹,Pandit Jayvardhan¹,Vajdos Felix F.¹,Vandeput Fabrice²,Yang Eddie¹,Menniti Frank S.⁵

Affiliation:

1. Pfizer World Wide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States

2. Division of Cardiovascular Medicine, University of Utah School of Medicine, 30 N 1900 E, Room 4A-100, Salt Lake City, Utah 84132, United States

3. Pfizer Worldwide Research and Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States

4. Pfizer World Wide Research and Development, La Jolla, California 92121, United States

5. MindImmune Therapeutics, Inc., and the George & Anne Ryan Institute for Neuroscience, University of Rhode Island, 7 Greenhouse Road, Kingston, Rhode Island 02881, United States

Funder

U.S. Department of Veterans Affairs

U.S. Department of Health and Human Services

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00374

Reference20 articles.

1. Differential function of phosphodiesterase families in the brain: gaining insights through the use of genetically modified animals

2. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective